Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
- None.
- None.
Insights
The decision by Hermann Bantleon GmbH to incorporate Mainz Biomed's ColoAlert® in its corporate health program represents a strategic investment in employee wellness, with implications for both healthcare cost management and workforce productivity. By facilitating early detection of colorectal cancer (CRC), Bantleon could potentially reduce long-term healthcare expenses and enhance overall employee health outcomes. The selection of ColoAlert®, known for its efficacy and ease of use, suggests a trend towards adopting innovative healthcare solutions within corporate wellness programs.
From a financial perspective, this initiative may signal underlying confidence in Mainz Biomed's product and could affect the company's stock valuation positively. Investors often look favourably upon companies that demonstrate strong corporate partnerships and adoption of their products in real-world settings. The timing of the rollout to coincide with CRC awareness month could also amplify the visibility of Mainz Biomed and its screening test, possibly leading to increased market demand and investor interest.
Colorectal cancer is the third most common cancer worldwide. The integration of ColoAlert® into Bantleon's health program underscores the importance of early detection in improving patient outcomes. ColoAlert®'s non-invasive nature and reported high efficacy could lead to higher screening rates among employees, which is critical given that early-stage CRC has a significantly better prognosis than advanced disease.
For healthcare professionals, the increased use of such tests could result in earlier interventions and a potential shift in CRC management strategies. However, it is essential to monitor the accuracy of ColoAlert® in a real-world corporate setting, as false positives or negatives could impact patient trust and healthcare resource allocation.
Implementing a health initiative like the ColoAlert® screening test reflects a growing recognition of the role of employers in supporting health and wellness. This proactive approach can contribute to a positive corporate culture and may serve as a recruitment and retention tool. By prioritizing the health of their employees, Bantleon not only addresses a critical health issue but also potentially enhances employee satisfaction and loyalty.
However, the success of such programs depends on employee participation rates and the effectiveness of the educational component provided by Mainz Biomed. Ensuring that employees understand the value and implications of the screening process is vital for the program's impact. It could also set a precedent for other companies to follow, potentially increasing the market for corporate health solutions.
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and Crimmitschau, in Q1 2024
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the second phase of its colorectal cancer (CRC) screening campaign through its BGM (“betriebliches Gesundheitsmanagement”) partnership with Bantleon, a shareholder of German AVIA and renowned for its high-performance lubricants and service solutions. Bantleon selected ColoAlert®, Mainz Biomed’s highly efficacious and easy-to-use screening test for CRC, for its corporate health program (BGM).
This continued BGM initiative follows a successful pilot program and will launch in Q1 2024 in line with CRC awareness month March. Via the Company’s BGM program, Bantleon offers ColoAlert® to its employees across all three sites in Germany – Ulm, Ulm-Nord and Crimmitschau. Bantleon employees are able to register using Mainz Biomed’s online portal and have the ColoAlert® test mailed to them. Once the sample is received and processed, confidential test results are returned to the employee through the portal, along with an explanation of the results. Employees can also approve for their physician to be notified of the test results in which case, their doctor can directly follow-up with them. As part of its commitment to the BGM program, Mainz Biomed provides education to employees and physicians on CRC and recommendations for next steps.
Rainer Janz, Head of Product and Quality Management at Bantleon, expressed enthusiasm about the ongoing collaboration, stating, "At Bantleon, we are committed to prioritizing the health and wellbeing of our employees. The feedback we received from our associates throughout the first phase of our CRC screening campaign was entirely positive. Mainz Biomed made it easy for us to implement the test in our BGM program and not only provided a convenient procedure for all participants but also fast and reliable results. We are looking forward to expanding our collaboration by offering ColoAlert® to our team members in a second CRC screening round."
Darin Leigh, Chief Commercial Officer at Mainz Biomed, added: “Early detection is key to increasing treatment options as well as survival rates for colorectal cancer patients. Screening at regular intervals is essential to detecting the disease in early stages where it can be successfully treated and dramatically improve patient outcomes. We applaud Bantleon for their highly progressive approach to the wellbeing of their employees and look forward to our continued collaboration as we work to spare more people from the devastating impacts of this disease.”
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About ColoAlert®
ColoAlert®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert® detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Dollinger et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert® will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
About Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert® should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com.
For media inquiries -
In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu
In the U.S.:
Josh Stanbury
+1 416 628 7441
josh@sjspr.co
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What is the partnership between Mainz Biomed N.V. and Hermann Bantleon GmbH about?
What is ColoAlert® At-Home Screening Test?
When will the BGM program offering ColoAlert® to employees launch?
How can employees register for ColoAlert® At-Home Screening Test?
What happens after the sample for ColoAlert® is received and processed?
What support does Mainz Biomed provide as part of its commitment to the BGM program?
